Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Campos (Miami, United States of America), P. Geraghty (New York, United States of America), G. Holt (Miami, United States of America), E. Donna (Miami, United States of America), E. Mendes (Miami, United States of America), L. Escobar (Miami, United States of America), L. Luna (Miami, United States of America), R. Stockley (Birmingham, United Kingdom). Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD). 571

Member's Comments

No comment yet.

Related content which might interest you: Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Epithelial cell biology Year: 2010 Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers. Source: International Congress 2017 – New Mechanistic Findings in COPD Year: 2017 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002 A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004 Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Alpha 1 - antitrypsin deficiency: diagnosis and treatment Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment Year: 2021 Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 Oral Presentation: Production of alpha-1 antitrypsin (AAT) by pro- and antiinflammatory macrophages and dendritic cells Source: Lung Science Conference 2011 - Immune system dysregulation in chronic lung disease Year: 2011 Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 499s Year: 2003 LSC 2011 Abstract: Production of alpha-1 antitrypsin (AAT) by pro- and anti-inflammatory macrophages and dendritic cells Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Similar pattern of interleukin-32 in AAT deficient and AAT replete patients with COPD Source: Annual Congress 2009 - COPD: basic science and clinical studies Year: 2009 Immune activation in α1 antitrypsin deficiency (AATD) emphysema: Beyond the protease/antiprotease hypothesis Source: Annual Congress 2012 - Mechanistic studies in airway cell biology Year: 2012 A phase 1B/2A study to evaluate the effect of aerosolized, recombinant alpha 1-antitrypsin (rAAT) on epithelial lining fluid (ELF) analytes in subjects with AAT deficiency Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005